The year 2026 marks a transformative era for the Oral Proteins and Peptide Market Developments, as capital flows into Asian biotechnology reach an all-time high. Strategic investment trends are shifting away from traditional small-molecule generics toward high-value, bio-engineered peptide platforms. In South Korea and China, venture capital activity has surged, specifically targeting...